Literature DB >> 26010613

IRF5: a rheostat for tumor-infiltrating lymphocyte trafficking in breast cancer?

Soizic Garaud1, Karen Willard-Gallo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26010613     DOI： 10.1038/icb.2015.39

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


× No keyword cloud information.
  12 in total

1.  CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

Authors:  Subir Biswas; Suman Sengupta; Sougata Roy Chowdhury; Samir Jana; Gunjan Mandal; Palash Kumar Mandal; Nipun Saha; Vivek Malhotra; Arnab Gupta; Dmitry V Kuprash; Arindam Bhattacharyya
Journal:  Breast Cancer Res Treat       Date:  2013-12-13       Impact factor: 4.872

2.  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

Authors:  Evangelia Razis; Konstantine T Kalogeras; Vassiliki Kotoula; Anastasia G Eleftheraki; Nikitas Nikitas; Ralf Kronenwett; Eleni Timotheadou; Christos Christodoulou; Dimitrios Pectasides; Helen Gogas; Ralph M Wirtz; Thomas Makatsoris; Dimitrios Bafaloukos; Gerasimos Aravantinos; Despina Televantou; Nicholas Pavlidis; George Fountzilas
Journal:  Clin Breast Cancer       Date:  2012-06       Impact factor: 3.225

3.  IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.

Authors:  Erica Maria Pimenta; Saurav De; Ryan Weiss; Di Feng; Kelly Hall; Sarah Kilic; Gyan Bhanot; Shridar Ganesan; Sophia Ran; Betsy J Barnes
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

4.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

5.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

Authors:  Chunyan Gu-Trantien; Sherene Loi; Soizic Garaud; Carole Equeter; Myriam Libin; Alexandre de Wind; Marie Ravoet; Hélène Le Buanec; Catherine Sibille; Germain Manfouo-Foutsop; Isabelle Veys; Benjamin Haibe-Kains; Sandeep K Singhal; Stefan Michiels; Françoise Rothé; Roberto Salgado; Hugues Duvillier; Michail Ignatiadis; Christine Desmedt; Dominique Bron; Denis Larsimont; Martine Piccart; Christos Sotiriou; Karen Willard-Gallo
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

6.  Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

Authors:  Monica Bodogai; Catalina Lee Chang; Katarzyna Wejksza; Jinping Lai; Maria Merino; Robert P Wersto; Ronald E Gress; Andrew C Chan; Charles Hesdorffer; Arya Biragyn
Journal:  Cancer Res       Date:  2013-01-30       Impact factor: 12.701

7.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Authors:  Christina Yau; Laura Esserman; Dan H Moore; Fred Waldman; John Sninsky; Christopher C Benz
Journal:  Breast Cancer Res       Date:  2010-10-14       Impact factor: 6.466

9.  Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers.

Authors:  Erica M Pimenta; Betsy J Barnes
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

10.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Authors:  J Panse; K Friedrichs; A Marx; Y Hildebrandt; T Luetkens; K Barrels; C Horn; T Stahl; Y Cao; K Milde-Langosch; A Niendorf; N Kröger; S Wenzel; R Leuwer; C Bokemeyer; S Hegewisch-Becker; D Atanackovic
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
View more
  4 in total

1.  Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer.

Authors:  Matthew Martin; Laiqing Hua; Benlian Wang; Han Wei; Lakshmi Prabhu; Antja-Voy Hartley; Guanglong Jiang; Yunlong Liu; Tao Lu
Journal:  J Biol Chem       Date:  2017-01-11       Impact factor: 5.157

Review 2.  Therapeutic Targeting of IRFs: Pathway-Dependence or Structure-Based?

Authors:  Cherrie D Thompson; Bharati Matta; Betsy J Barnes
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

3.  Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer.

Authors:  Dan-Dan Feng; Qian Cao; Dao-Qi Zhang; Xiao-Lu Wu; Cai-Xia Yang; Yu-Fei Chen; Tang Yu; Hai-Xiao Qi; Guo-Ping Zhou
Journal:  Onco Targets Ther       Date:  2019-08-23       Impact factor: 4.147

4.  SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer.

Authors:  Qin Huo; Zhenwei Li; Lixin Cheng; Fan Yang; Ni Xie
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.